These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17485898)

  • 1. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
    Hatake K; Tokudome N; Ito Y
    Breast Cancer; 2007; 14(2):132-49. PubMed ID: 17485898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of ErbB inhibitors in trastuzumab resistance.
    Miller KD
    Oncologist; 2004; 9 Suppl 3():16-9. PubMed ID: 15163843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
    Stanley A; Ashrafi GH; Seddon AM; Modjtahedi H
    Sci Rep; 2017 Jun; 7(1):3964. PubMed ID: 28638122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 6. HER-2-positive breast cancer: hope beyond trastuzumab.
    Bartsch R; Wenzel C; Zielinski CC; Steger GG
    BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.
    Burris HA
    Oncologist; 2004; 9 Suppl 3():10-5. PubMed ID: 15163842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
    Baselga J
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii281-8. PubMed ID: 18790967
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
    Zhong H; Bowen JP
    Curr Top Med Chem; 2011; 11(12):1571-90. PubMed ID: 21510831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
    O'Donovan N; Byrne AT; O'Connor AE; McGee S; Gallagher WM; Crown J
    Invest New Drugs; 2011 Oct; 29(5):752-9. PubMed ID: 20229355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
    Zhang S; Huang WC; Zhang L; Zhang C; Lowery FJ; Ding Z; Guo H; Wang H; Huang S; Sahin AA; Aldape KD; Steeg PS; Yu D
    Cancer Res; 2013 Sep; 73(18):5764-74. PubMed ID: 23913825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
    Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
    Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
    Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies in breast cancer: where are we now?
    Di Cosimo S; Baselga J
    Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.